Drug insight: Emerging new drugs in the treatment of myelodysplastic syndromes

Nature Clinical Practice Oncology

Volumn 2, Issue 7, 2005, Pages 348-355

  Faderl, Stefan ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 azacytidine; Decitabine; Hypomethylating agents; Lenalidomide; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; AZACITIDINE; BEVACIZUMAB; CEP 701; CYTIDINE DERIVATIVE; CYTOKINE ANTIBODY; DEPSIPEPTIDE; ETANERCEPT; FLT3 LIGAND; FR 901228; GLUTATHIONE DERIVATIVE; GLUTATHIONE TRANSFERASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INFLIXIMAB; LENALIDOMIDE; LONAFARNIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NEW DRUG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TELINTRA; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TIPIFARNIB; TLK 199; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DNA METHYLATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 23844512832     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0224     Document Type: Review

References (55)

1. Heaney ML and Golde DW (1999) Myelodysplasia. N Engl J Med 340: 1649-1660
2. Steensma DP and Tefferi A (2003) The myelodysplastic syndrome(s): A perspective and review highlighting current controversies. Leuk Res 27: 95-120
3. Faderl S and Kantarjian HM (2004) Novel therapies for myelodysplastic syndromes. Cancer 101: 226-241
4. Aul C et al. (1998) Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 22: 93-100
5. Germing U et al. (2004) No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 89: 905-910
6. Park DJ and Koeffler HP (1996) Therapy-related myelodysplastic syndromes. Semin Hematol 33: 256-273
7. Estey EH (1998) Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica 83: 543-549
8. Albitar M et al. (2002) Myelodysplastic syndrome is not merely "preleukemia". Blood 108: 791-798
9. Rosenfeld C and List A (2000) A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies. Leukemia 14: 2-8
10. Mufti GJ (2004) Pathobiology, classification, and diagnosis of myelodsyplastic syndromes. Best Prac Res Clin Haematol 17: 543-557
11. Barrett J et al. (2000) Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 37: 15-29
12. Allampallam K et al. (2001) Cytokines and MDS. Cancer Treat Res 108: 93-100
13. Killick SB et al. (2003) A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 120: 697-684
14. Lancet JE and Karp JE (2003) Farnesyltransferase inhibitors in hematologic malignancies: New horizons in therapy. Blood 102: 3880-3889
15. + cells from normal and myelodysplastic bone marrow. Blood 100: 3553-3560
16. Giagounidis AA et al. (2004) The 5q- syndrome. Hematology 9: 271-277
17. Bennett JM et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199
18. Harris NJ et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1977. J Clin Oncol 17: 3835-3849
19. Nösslinger T et al. (2001) Myelodysplastic syndromes, from French-American-British to World Health Organization: Comparison of classification on 431 unselected patients from a single institution. Blood 98: 2935-2941
20. Howe RB et al. (2004) The WHO classification of MDS does make a difference. Blood 103: 3265-3270
21. Greenberg P et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088
22. [No authors listed] (1998) NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network. Oncology (Huntingt) 12: 53-80
23. Aul C et al. (2002) Myelodysplastic syndromes. Diagnosis and therapeutic strategies. Med Klin (Munich) 97: 666-676
24. List AF (2002) New approaches to the treatment of myelodysplasia. Oncologist 7 (Suppl 1): S39-S49
25. Rowe JM (2004) State of the science for myelodysplastic syndrome: prognosis and promise of new therapies. Best Pract Res Clin Haematol 17: 535-541
26. Cheson BD et al. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671-3674
27. Cheson BD et al. (2001) Myelodysplastic syndromes standardized response criteria: Further definition. Blood 98: 1985
28. Galustian C et al. (2004) Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 4: 1963-1970
29. Mitsiades CS and Mitsiades N (2004) CC-5013 (Celgene). Curr Opin Investig Drugs 5: 635-647
30. List A et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352: 549-557
31. List A et al. (2003) Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS) [abstract]. Blood 102: A184
32. List A et al. (2003) Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 17: 1499-1507
33. Vey N (2004) Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 5: 613-621
34. Vey N et al. (2003) Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase 1/2 study [abstract]. Blood 102: A422
35. List AF et al. (2003) Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary findings in a phase 2 clinical study [abstract]. Blood 102: A423
36. Raza A et al. (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28: 791-803
37. Meng F et al. (2001) TLK199: A novel, small molecule myelostimulant [abstract]. Proc Amm Mtg Am Assoc Cancer Res 42: A214
38. Ruscoe JE et al. (2001) Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 298: 339-345
39. Faderl S et al. (2003) Hematologic improvement following treatment with TLK199 (a novel glutathione analog inhibitor of GST P1-1) in myelodysplastic syndrome (MDS): Interim results of a phase 1-2a study [abstract]. Blood 102 (Suppl 1): AS426
40. Callander N et al. (2004) Hematologic improvement following treatment with TLK199 (Telintra™), a novel glutathione analog inhibitor of GST P1-1, in myelodysplastic syndrome (MDS): Interim results of a dose-ranging phase 2a study [abstract]. Blood 104: A400
41. Santini V et al. (2001) Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134: 573-586
42. Issa JP et al. (1997) DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 11 (Suppl 1): S7-S11
43. Daskalakis M et al. (2002) Demethylation of a hypomethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964
44. Silverman LR et al. (1994) 5-azacytidine in myelodysplastic syndromes (MDS): The experience at Mount Sinai Hospital, New York. Leuk Res 18: 21
45. Silverman L et al. (1994) Azacytidine (azaC) in myelodysplastic syndromes (MDS); CALGB 8421 and 8921 [abstract]. Ann Hematol 68: A12
46. Silverman LR et al. (2002) Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429-2440
47. Kornblith AB et al. (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 20: 2441-2452
48. DeSimone J et al. (2002) Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99: 3905-3908
49. Koshy M et al. (2000) 2-deoxy-5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96: 2379-2384
50. Wijermans P et al. (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18: 956-962
51. Wijermans PW et al. (2002) Low dose decitabine for elderly high risk MDS patients: Who will respond? [abstrAct] Blood 100: a96
52. 2/course) in myelodysplastic syndrome (MDS) [abstract]. Blood 104: A402
53. Issa J-P et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640
54. Saba H et al. (2004) First report of the phase III North American Trial of decitabine in advanced myelodysplastic syndrome (MDS) [abstract]. Blood 104: A23
55. Garcia-Manero G et al. (2004) Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine (DAC) and valproic acid (VPA in patients (pts) with leukaemia [abstract]. Blood 104: A78